Is Intuitive Surgical Inc (ISRG) undervalued or overvalued?

Our model estimates a fair value of about $287 against a price of $426.70 (Overvalued, -33% to fair value). It blends a 10-year DCF, sector multiples and earnings-power value and is a model estimate, not advice.

What is the X-Ray Score for ISRG?

Intuitive Surgical Inc has an X-Ray Score of 61 out of 100, built from valuation, growth, profitability, financial health and dividend lenses ranked against Health Care peers.

Where does the data for ISRG come from?

Financial statements come from SEC EDGAR filings, prices from exchange price feeds, and industry betas and equity risk premium from Damodaran Online (NYU Stern).

Intuitive Surgical Inc (ISRG)

Health Care · Health Care Equipment · US stock · S&P 500 component

$426.70 ▼ -1.16 (0.27%)

At close 16 Oct 2026 · USD · Volume 2,609,600

Compare with RMD Historical data Research report SEC filings

Fair valueOvervalued

$287 −32.7% to fair value

$144fair band $201–$373$431

Day's range

$425.51 – $434.89

52-week range

$328.57 – $603.88

About Intuitive Surgical Inc

Intuitive Surgical makes the da Vinci robotic-assisted surgical systems, which surgeons use to perform minimally invasive procedures, along with the Ion system for lung biopsy. Hospitals acquire or lease the systems, and then order instruments, accessories and service plans for them. Revenue therefore combines system sales and leases with recurring income from instruments and services that rise with the number of procedures performed.

Sales reached $11.0 billion in the last twelve months, having grown 17.4% a year over the past three years. Operating profit equals 31.3% of revenue. Return on invested capital is 22%. No dividend is paid. Overall, the X-Ray Score is 61 out of 100. These numbers describe past results and current financial position, and they are shown for reference only.

Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.

Price chart

Historical data & CSV

52-wk range $328.57 – $603.88Volume 2,609,600Daily, split-adjusted

Vitals

Market cap$152.5B

52-week range$328.57 – $603.88

Volume (last day)2,609,600

P/E (TTM)49.0

EBIT / EV yield2.3%

Free-cash-flow yield2.1%

Dividend yieldNo dividend

Revenue (TTM)$11.0B

Net income (TTM)$3.1B

Operating margin31.3%

Return on capital22.1%

Debt incl. leasesData missing

Cash & securities$5.2B

Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.

Fair value estimate

$287model spread $257 – $317

Overvalued −32.7% to fair value

Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.

Price $427

Undervalued < $201Fair $201 – $373Overvalued > $373

10-year DCF (market-scaled)

$386

Peer multiples

$238

Earnings power floor (not blended)

$96

Fundamentals-adjusted multiple

$238

Growth the price implies

29.2%/yr

A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.

What this means

Healthy business, but priced high

Our models put fair value below today's price, so a lot of good news may already be in the price. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.

Before you invest · decision checklist

I understand how this company makes money Business quality is average or better ✓ 73 The price is not above fair value $287 fair value Debt looks manageable Revenue has been growing 17.4% a year Profits are backed by cash There are no red flags none raised I know what share of my savings this would be

Ticked boxes are filled in from our data; the rest are yours to answer.

The five-lens scan

Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.

Valuation Weak

20/100

Expensive against its sector on earnings and cash flow.

See the numbers →

EBIT / EV yield2.3%

Free-cash-flow yield2.1%

Fair value vs price0.7×

Growth Strong

86/100

Growing faster than most of its sector.

See the numbers →

Revenue growth (3y)17.4%

EPS growth (3y)29.2%

Growth consistency100%

Profitability Fair

65/100

Returns on capital are typical for its sector.

See the numbers →

Return on invested capital22.1%

Operating margin31.3%

Gross profitability35.2%

Financial health Strong

80/100

Balance sheet looks strong: debt is well covered.

See the numbers →

Piotroski F-Score7 / 9

Interest coverNo interest cost

Dividends None

–/100

Pays no dividend.

See the numbers →

Quarterly results: last 6 quarters

+19.2%

Mar '25

+21.4%

Jun '25

+22.9%

Sep '25

+18.8%

Dec '25

+23.0%

Mar '26

+18.5%

Jun '26

Revenue against the same quarter a year earlier. Latest quarter revenue $2.9B, diluted EPS $2.29.

Compare with peers

RMD Resmed Inc73 DXCM Dexcom Inc71 PODD Insulet Corp69 IDXX Idexx Laboratories Inc67

Other Health Care Equipment companies by X-Ray Score.

Fundamentals checklist

● 9 Good · ● 3 Average · ● 3 Bad

Cash quality

Earnings backed by cashAverage

Free-cash-flow yieldBad

Risk models

Altman Z''Good

Piotroski F-ScoreAverage

Growth

EPS growth (3y)Good

Free-cash-flow growth (3y)Good

Revenue growth (3y)Good

Growth consistencyGood

Balance sheet

Current ratioGood

Interest coverGood

Valuation

Fair value vs priceBad

EBIT / EV yieldBad

Profitability

Return on invested capitalGood

Operating marginGood

Gross profitabilityAverage

Each check is graded against the company's sector, not a fixed number. Checklist score 62/100.

Financials

	FY21	FY22	FY23	FY24	FY25
Revenue	$5.7B	$6.2B	$7.1B	$8.4B	$10.1B
Operating income	$1.8B	$1.6B	$1.8B	$2.3B	$2.9B
Net income	$1.7B	$1.3B	$1.8B	$2.3B	$2.9B
Operating cash flow	$2.1B	$1.5B	$1.8B	$2.4B	$3.0B
Operating margin	31.9%	25.3%	24.8%	28.1%	29.3%
Free cash flow	$1.7B	$958M	$750M	$1.3B	$2.5B
Diluted EPS	$4.66	$3.65	$5.03	$6.42	$7.87

Fiscal years, from SEC filings.

Technical summary

Daily

Bullish

10 bullish · 1 neutral · 5 bearish

Weekly

Neutral

6 bullish · 1 neutral · 5 bearish

Monthly

Strongly bearish

1 bullish · 1 neutral · 6 bearish

Moving averages (daily)

SMA 10	419.0	Bullish
EMA 10	419.3	Bullish
SMA 20	411.2	Bullish
EMA 20	410.6	Bullish
SMA 50	391.7	Bullish
EMA 50	398.9	Bullish
SMA 100	392.8	Bullish
EMA 100	404.7	Bullish
SMA 200	439.6	Bearish
EMA 200	428.8	Bearish

Oscillators (daily)

RSI (14)	64.71	Neutral
MACD (12, 26)	10.84	Bullish
Momentum (12)	4.94	Bullish
Stochastic %K (14)	82.11	Bearish
Williams %R (14)	-17.89	Bearish
CCI (20)	138.6	Bearish

Pivot points (classic, last session)

413.8

419.7

423.2

Pivot

429.0

432.6

438.4

441.9

Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.